Phone :+91-(522)-2772450/2772550 Search

Cancer Biology
  • This is newly established research area in CSIR-CDRI that consists of dedicated scientists and more than 75 research scholars from Biological as well chemical sciences having skills and expertise in a broad range of cancer-related fields. Our long term goals are to understand fundamental molecular mechanisms in oncogenesis and utilizing this information for translational directions related to the rational drug designing, prevention, diagnosis, prognosis and treatment of human cancers. The faculties conduct both basic and translational research on a range of topics that include lung, brain, oral, breast, cervical cancers and leukemias etc. Our current focus is on identification of lead synthetic compounds/pure compounds from natural sources having in-vitro anti-proliferative activities against different cancer cell lines and understanding alterations and cross-talks among signalling pathways in cancers. Emphasis is also given on characterization of novel drug targets and identification of target-specific leads (for clinically validated Targets HDAC, AKT, mTOR and Proteasomes). Repurposing of clinically validated drugs for new uses, development of new chemical entities (NCEs) and optimization of lead molecules by development of in-silico library of compounds through pharmacophore modelling and structure-based drug design, drug delivery, in vivo efficacy, pharmacokinetics and in-vivo toxicity/safety pharmacology are some of current activities in this research area. Characterization and targeting of cancer stem cells from various cancer types is another forte. Development of animal models of tumor and related facilities are our major future goal to understand mechanism of action of lead molecules and repurposing of clinically validated drugs in vivo. Scientists of this area belonging to interdisciplinary groups within institute and collaboration with clinicians from various hospitals make this area a vibrant and rapidly growing research group with sole objective to provide better insights for understanding cancer biology and deliver cost effective healthcare by offering novel diagnostics and therapeutics in cancers.

  • mTORC1-Akt dual inhibitor: 
    S016-0278 is a hit identified as mTORC1-Akt dual inhibitor. Further optimization to qualify as lead is underway. 

  • SMAC Mimetic: 
    S016-1348 is a hit identified as SMAC mimetic.

Scientists Associated With The Project

Team Members